How a drug becomes "ethnic": law, commerce, and the production of racial categories in medicine.

摘要: A drug called BiDil is poised to become the first pharmaceutical ever approved by U.S. Food and Drug Administration (FDA) treat heart failure specifically in African Americans—and only Americans. On March 8, 2001, NitroMed, then a privately held biotech firm Massachusetts, issued press release triumphantly announcing receipt of letter from FDA “describing regulatory status ultimate approvability BiDil®,” pending successful completion confirmatory trial Americans with failure. Press reports have already touted this breakthrough as “ethnic”